Sana Biotechnology to Present at May 2023 Investor Conferences
03 Maio 2023 - 5:05PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
changing the possible for patients through engineered cells, today
announced that it will webcast its presentations at two
investor conferences in May. The presentations will feature a
business overview and update by Steve Harr, Sana’s President and
Chief Executive Officer and Nate Hardy, Sana’s Chief Financial
Officer.
- Steve Harr will present at the BofA Securities 2023 Healthcare
Conference at 2:20 p.m. PT on Tuesday, May 9, 2023.
- Nate Hardy will present at the JMP Securities Life Sciences
Conference at 10:00 a.m. ET on Monday, May 15, 2023.
The webcasts will be accessible on the Investor Relations page
of Sana’s website at https://sana.com/. A replay of each
presentation will be available at the same location for 30 days
following the corresponding conference.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision; the Company’s
participation in the BofA Securities 2023 Healthcare Conference and
the JMP Securities Life Sciences Conference; and the subject matter
of the Company’s presentations at those conferences. All statements
other than statements of historical facts contained in this press
release, including, among others, statements regarding the
Company’s strategy, expectations, cash runway and future financial
condition, future operations, and prospects, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials, as well as the economic, market and social
disruptions due to the ongoing COVID-19 public health crisis. For a
detailed discussion of the risk factors that could affect the
Company’s actual results, please refer to the risk factors
identified in the Company’s SEC reports, including but not limited
to its Annual Report on Form 10-K dated March 16, 2023. Except as
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements for any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sana Biotechnology (NASDAQ:SANA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024